𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients

✍ Scribed by A. Gramenzi; E. Loggi; L. Micco; C. Cursaro; S. Fiorino; S. Galli; S. Gitto; C. Galli; G. Furlini; M. Bernardi; P. Andreone

Book ID
108886615
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
152 KB
Volume
18
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Loss of hepatitis B surface antigen from
Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine
✍ Mariko Kobayashi; Fumitaka Suzuki; Norio Akuta; Tetsuya Hosaka; Hitomi Sezaki; H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

## Abstract Although loss of hepatitis B e antigen (HBeAg) from the serum is sought by treatment with lamivudine, clearance of hepatitis B surface antigen (HBsAg) is the eventual goal of any antiviral therapy. In a single hepatology center in the Metropolitan Tokyo, 486 patients with chronic hepati

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60